What is Immunovant, Inc.'s pre-tax income?

Immunovant, Inc. (IMVT) reported pre-tax income of -$150.7M in Q1 2026.

How has Immunovant, Inc.'s pre-tax income changed year-over-year?

Immunovant, Inc.'s pre-tax income decreased by 42.3% year-over-year, from -$105.87M to -$150.7M.

What is the long-term trend for Immunovant, Inc.'s pre-tax income?

Over 4 years (2022 to 2026), Immunovant, Inc.'s pre-tax income has grown at a 34.0% compound annual growth rate (CAGR), from -$156.81M to -$505.39M.

What does pre-tax income mean?

Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Immunovant, Inc. (IMVT) Pre-Tax Income

Screener

Pre-Tax Income at other companies

Johnson & JohnsonJNJ

$6.75B+3.9%

United Community BanksUCB

$149.17M+48.4%

Apogee Therapeutics, Inc.APGE

-$74.03M-34.0%

Vera TherapeuticsVERA

-$74.9M-96.9%

Avalo TherapeuticsAVTX

-$36.34M-75.1%

Segments

By geography

See full

Switzerland-$606.29M-53.4%

United States$100.99M+670%

United Kingdom-$55K—

Bermuda-$39K+61.0%

Other financials

Income statement

See full

Net income-$147.9M-38.9%

EPS (diluted)-$0.73-15.9%

Balance sheet

See full

Cash & equivalents$902.1M+26.4%

Total debt$72.0K-26.5%

Total equity$852.6M+20.5%

Total assets$957.0M+23.3%

Cash flow

See full

Operating cash flow-$95.1M+14.1%

CapEx$8.0K-96.0%

Free cash flow-$95.1M+14.2%

Valuation

See full

Market cap$8.21B+201%

Enterprise value$7.31B+89.7%

Returns & leverage

See full

Return on equity-64.8%+2.5pp

Debt / equity0×0.0×

Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.

Filed: May 20, 2026, 7:28 AM EDT
Fiscal year: FY2026
Accession: 0001764013-26-000064

Line item	Years Ended March 31, 2026	Years Ended March 31, 2025	Years Ended March 31, 2024
Total operating expenses	532,902	438,152	282,709
Interest income, net	(25,330)	(24,732)	(24,948)
Other (income) expense, net	(2,181)	(471)	1,008
Loss before provision for income taxes	(505,391)	(412,949)	(258,769)
Provision for income taxes	215	891	567
Net loss	$(505,606)	$(413,840)	$(259,336)
Net loss per common share — basic and diluted	$(2.77)	$(2.73)	$(1.88)
Weighted average common shares outstanding — basic and diluted	182,421,233	151,573,553	138,100,577

Item 8. Financial Statements and Supplementary Data

FAQ

What is Immunovant, Inc.'s pre-tax income?: Immunovant, Inc. (IMVT) reported pre-tax income of -$150.7M in Q1 2026.
How has Immunovant, Inc.'s pre-tax income changed year-over-year?: Immunovant, Inc.'s pre-tax income decreased by 42.3% year-over-year, from -$105.87M to -$150.7M.
What is the long-term trend for Immunovant, Inc.'s pre-tax income?: Over 4 years (2022 to 2026), Immunovant, Inc.'s pre-tax income has grown at a 34.0% compound annual growth rate (CAGR), from -$156.81M to -$505.39M.
What does pre-tax income mean?: Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.